Search This Blog

Monday, July 1, 2019

FDA OKs Foundation Med’s FoundationOne CDx Lynparza companion

The FDA has approved Roche (OTCQX:RHHBY +0.7%) unit Foundation Medicine’s FoundationOne CDx molecular test as a companion diagnostic for AstraZeneca’s Lynparza (olaparib) for first-line maintenance therapy in BRCA mutation-positive ovarian cancer.
The companies and Merck are also collaborating on developing companion diagnostics for Lynparza in prostate cancer.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)